


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61B 19/00, A61F 2/12	A1	(11) International Publication Number: WO 95/07057 (43) International Publication Date: 16 March 1995 (16.03.95)
(21) International Application Number: PCT/US94/10222 (22) International Filing Date: 7 September 1994 (07.09.94) (30) Priority Data: 08/116,587 7 September 1993 (07.09.93) US (71) Applicant: DATASCOPE INVESTMENT CORP. [US/US]; 14 Philips Parkway, Montvale, NJ 07645 (US). (72) Inventors: JANZEN, Ernst; Stadelkruid 8, NL-1251 GR Laren (NL). HOEKSTRA, Matthias, Johannes; Logger 147, NL-1186 RP Amstelveen (NL). DUTRIEUX, Richard, P.; J. Huizingalaan 403, NL-1066 TX Amsterdam (NL). DAMINK, Leonardus, Hermannus, Hendrikus, Olde; Aan de Weverij 17, NL-6291 HV Vaals (NL). (74) Agent: SCHAEFFER, David, L.; Fitzpatrick, Cella, Harper & Scinto, 277 Park Avenue, New York, NY 10172 (US).		(81) Designated States: AU, BR, CA, CN, JP, KR, RU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: IMPROVED SOFT TISSUE IMPLANT (57) Abstract <p>Soft tissue implants (10) can be constructed by forming an outer membrane into a closed pouch (14) and filling material (16) in that pouch (14). A composition for use as a filler material (16) in such a soft tissue implant (10) may include elastin and collagen. The filling material (16) has collagen as a component thereof, and this collagen can be cross-linked. Methods of making such implants are described.</p> 		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLEIMPROVED SOFT TISSUE IMPLANT5 BACKGROUND OF THE INVENTIONField of the Invention

10 The present invention relates to soft tissue implants,
often referred to as prostheses. Such implants have
particular utility for breast augmentation and breast
reconstruction.

Related Background

15 Over the years, many attempts have been made to develop
prosthesis suitable for breast implants.

20 At first, breast augmentation was accomplished by means
of injecting liquids, primarily silicone gel, directly
into the soft tissue of the breast. That silicone gel,
however, was soon found to migrate, causing serious
medical problems. To solve the migration problem, the
next step was to encapsulate the silicone gel in a
25 pouch or envelope made of some impervious material,
often silicone, and then surgically implant the pouch
in the breast.

- 2 -

Unfortunately, that approach brought with it a new set of problems. It was soon found that the body's defense mechanisms cause the formation of a natural tissue capsule around the breast prosthesis thereby enclosing and isolating it from the surrounding body tissue. This fibrous tissue capsule, containing fibroblasts, myofibroblasts and inflammatory cells, has a continuous tendency to contract, thereby tightening around the implant and causing it to become very firm. Contracture can also lead to tenderness of the breast, pain, erosion of the adjacent tissue as well as other complications.

To further exacerbate the problem, studies have shown that the silicone gel fillers found in many breast prosthesis tend to "bleed" through the membrane envelope causing a chronic inflammatory response in the surrounding tissue. This chronic inflammatory response also leads to natural tissue encapsulation and eventually to contracture.

Numerous attempts have been made to overcome the contracture problem. For example, U.S.P. 4,298,998 proposes using a double walled or "dual lumen" prosthesis with an absorbable outer wall and an absorbable filler material between the inner and outer walls. U.S.P. 4,772,284 proposes using a more biocompatible filler material, for example, collagen gels and saline. U.S.P. 4,840,628 describes a prosthesis that has neither a liquid core nor a permanent enclosing membrane. Instead, it suggests using a cast silicone gel elastomer having a homogeneous cohesive structure throughout. In addition, that casting may be covered with a minimum membrane coating or an absorbable shell.

- 3 -

The present invention addresses the encapsulation/contracture/inflammatory response problems by using all natural materials rather than silicone or the like.

5

Summary of the Invention

The soft tissue implant of the present invention is comprised of an envelope or pouch, defined by a thin membrane, and a filler. The envelope membrane is made of a collagen/elastin matrix of natural origin and the filler is made of elastin and collagen fibers. The native matrix is more than a scaffold alone and maintains a dynamic relationship with the ingrowing cells.

15

As used herein, the term "elastin" is intended to encompass protein elastin as well as the combination of elastin with microfibrils, which combination is often referred to in the technical literature as elastic fibers.

20

The envelope membrane is preferably derived from animal membrane which has been cleaned of non-collagenous and non-elastinous proteins. Because it contains only natural materials, materials which, in their cleaned states, are non-antigenic or only minimally antigenic, the membrane does not cause the kind of chronic inflammatory response which is common with artificial materials such as silicone. As a result, a chronic tissue reaction and encapsulation does not occur and there is no contracture with which to be concerned.

25

30

Similarly, the filler material is composed of natural materials, namely, cleaned collagen and elastin fibers, without any cross-linking agents. Since the filler is comprised of non-antigenic or only minimally antigenic

35

- 4 -

materials, "bleeding" of the filler material through the membrane is of no concern. Hence, neither the membrane nor the filler is likely to cause a chronic inflammatory reaction and tissue encapsulation with contracture.

Preferred animal tissue starting materials for the envelope membrane include the peritoneum and omentum. Other suitable membrane starting materials include other natural membranes such as amnion, chorion, pleura, pericardium, facia lata, dura mater, intestine or dermis. While these membranes can be obtained from many animal species, the most readily available are membranes of bovine, porcine or ovine origin.

The filling material may be derived from ligaments, tendons or membranes, commonly of bovine, porcine or ovine origin. The preferred starting material for making the filler for use in the present invention is the bovine ligamentum nuchae because of its high elastin content.

Description Of The Drawings

Figure 1 is a section through a female breast showing a soft tissue implant according to the present invention.

Detailed Description

Figure 1 depicts a soft tissue implant 10 according to the present invention having been implanted in a female breast 12. The implant or prosthesis 10 is comprised of an envelope or pouch 14 and filler material 16. The filler material is comprised primarily of collagen and elastin fibers whereas the pouch is made of an elastin/collagen membrane derived from natural animal tissue.

- 5 -

Preferred pouch membrane starting materials include bovine or porcine peritoneum or omentum. These tissues are cleaned of non-collagenous and non-elastinuous proteins by a process which does not destroy the natural collagen/elastin matrix. One suitable cleaning method is described in U.S.P. 5,028,695, the disclosure of which is incorporated herein by reference.

Basically, the cleaning process is carried out by first washing the membranes and subjecting them to a strong alkali treatment, preferably by soaking them in a sodium hydroxide (NaOH) solution. Other suitable alkali treatments might include potassium hydroxide (KOH) or calcium hydroxide (CaOH). After washing again with water, the membranes are treated with a strong acid, preferably hydrochloric acid (HCl). Other suitable acids might include sulfuric acid (H₂SO₄) and acetic acid (C₂H₄O₂). Washing then removes most of the acid, and that which remains is neutralized by use of a base, preferably bicarbonate of soda (NaHCO₃). Other suitable neutralizing agents might include sodium acetate (NaC₂H₃O₂) and de-sodium hydrogen phosphate. The resulting salts are then removed by washing in water, following which the water is removed, for example, by acetone extractions, and the membranes are air dried to remove the residual acetone.

While it is believed unnecessary and, indeed, preferable not to cross-link the collagen in the pouch membrane, cross-linking may be used for some applications, for example, it is possible that some cross linking may assist in decreasing the degradation rate. If there is to be cross-linking, the cross-linked collagen should be non-cytotoxic and should not provoke cellular or immune responses. Hexamethylene diisocyanate may be one such cross-linking agent, as may some polyepoxy compounds, for example, polyethylene

SUBSTITUTE SHEET (RULE 26)

- 6 -

glycol diglycidyl ether and water soluble carbodiimides, for example, 1-ethyl-3[3-dimethyl amino propyl]carbodiimide.HCl in the presence of N-hydroxysuccinimide. Since the cross-linking agents are
5 believed to form very stable bonds with the collagen, they produce cross-linked collagen which is non-cytotoxic and is not likely to provoke any immune or cellular response.

10 Preferred filler starting materials include ligaments and tendons. In particular, the starting material believed to be most suitable is bovine ligamentum nuchae because it is made up largely of elastin, with
15 only a relatively small amount of collagen. Indeed, more than 70% of the dry weight of this ligament is elastin. The relatively high elastin content and relatively low collagen content make it an ideal starting material for the filler material of the
20 present invention.

As noted above, the term "elastin" is used herein to include elastin together with microfibrils. Elastin in natural tissue is normally associated with microfibrils and, for the purpose of the present invention, no
25 effort is made to remove the microfibrils. While, in its broadest scope, the present invention covers the use of elastin which has had the microfibrils removed, it is believed preferable not to remove them.

30 To make a preferred filler material according to the present invention, the ligamentum nuchae may be cleaned using a process similar to that taught in U.S.P. 5,028,695. The ligament is first cleaned of blood and adherent tissue and then is chemically treated to
35 remove the non-elastinous and non-collagenous components. The chemical treatment preferably includes subjecting the ligament to a strong alkali treatment

- 7 -

then to an acid treatment and then to a neutralizing bath. A preferred alkali treatment involves soaking in a sodium hydroxide (NaOH) bath. Other suitable alkali agents include potassium hydroxide and calcium
5 hydroxide. A preferred acid for the acid treatment is hydrochloric acid (HCl) although other acids, such as sulfuric acid and acetic acid, might also be suitable. As for the neutralizing step, many suitable bases are available, the preferred one being bicarbonate of soda
10 (NaHCO_3), while other neutralizing agents might include sodium acetate and de-sodium hydrogen phosphate.

The chemical treatment is followed by mechanical manipulation which separates the elastin and collagen
15 fibers. The separated fibers are then dried, preferably without cross-linking. However, it might be possible to decrease the degradation time if the collagen were cross-linked so as to produce a non-cytotoxic material that does not provoke a cellular or
20 immune response. Suitable cross-linking agents might include a hexamethylene diisocyanate, a polyepoxy compound, or a water soluble carbodiimide as discussed above.

25 Although the preferred filler starting material is the ligamentum nuchae, other starting materials may also be used. For example, the peritoneum and omentum membranes have about 15% elastin and could also be used to make a filler material in accordance with the
30 present invention. In addition, elastin and collagen from different sources could be mixed together to produce a mix having whatever proportions are deemed advantageous for a particular application. It is
35 believed, however, that the composition should have minimum of perhaps as little as about 10% elastin (dry weight) and might have as much as 90% or perhaps even higher of elastin.

- 8 -

While, as noted, it is believed preferable for the filler to contain both collagen and elastin, elastin alone without collagen might also be suitable. Similarly, collagen without elastin might be used, particularly if that collagen is cross linked with an agent that does not reach out and produces a non-cytotoxic composition that does not provoke a significant immune or cellular response. Such suitable cross-linking agents might include the hexamethylene diisocyanate, polyepoxy compounds and water soluble carbodiimides referred to above.

It has been found that the cleaned membranes prepared in accordance with this invention have a mesothelial side 18 and a loose connective tissue side 20. The pouch 14 is made with the loose connective tissue side facing out because when implanted with the loose connective tissue side out, it is believed that the pouch will rapidly become anchored in place as a result of fibrovascular ingrowth from the surrounding tissue.

Unlike the prior art prosthesis, the implant of the present invention employs a porous membrane to form the envelope. A porous membrane is made possible because the filler material 16 is made up of cleaned natural fibers, namely elastin and collagen, which have very low antigenicity and hence cause only minor and transitory inflammatory response.

In addition to being porous, the envelope membrane, has very low antigenicity and produces only a very minor inflammatory response. Moreover, because the loose connective tissue side which faces out promotes vascularization, the membrane quickly becomes integrated into the surrounding tissue without the formation of the fibrous encapsulation and contracture which is found in the prior art.

- 9 -

It is believed that once the prosthesis of the present invention is implanted, the collagen in the membrane causes some mild transitory tissue reaction in the surrounding tissue and, therefore, some increased
5 vascular activity. Vascularization of the implant membrane begins while the collagen in that membrane is being resorbed and proceeds through the membrane and into the collagen/elastin filler material. This
10 vascular ingrowth through the membrane into the filler material leads to resorption of the collagen, both in the membrane matrix and in the filler material.

As vascularization and resorption of the collagen in the filler material is going forward, fibroblasts are
15 activated. Those fibroblasts, which appear to have a affinity for elastin, attach themselves to the elastin fibers and lay down an organized matrix of new native connective tissue.

20 The natural vascularization which occurs and the integration of the envelope membrane into the surrounding tissue may make suturing of the envelope in place unnecessary. If however, such suturing is deemed
25 advisable, it can easily be done, preferably with non-absorbable suture material like prolene.

In this connection, it should be noted that suturing can be done both easily and without creating any additional risk. The envelope membrane, being composed
30 of a natural elastin/collagen matrix, will readily close any hole made by a needle and suture. Moreover, even if the natural sealing of the holes is not complete, slight leaks of filler material are of no concern because, as discussed above, the filler
35 material is made up of cleaned collagen and elastin, both of which are either non-antigenic or, at worst, only minimally antigenic.

- 10 -

While it is believed most desirable for the membrane to consist of a natural collagen or collagen/elastin matrix, the filler material herein disclosed can be used in any pouch. For example, if it is determined
5 that the primary problems with present day pouches relates to the filler material rather than the pouch membrane material, the filler of the present invention could be substituted for that prior art filler without changing the pouch membrane. Thus, a pouch made of a
10 silicone membrane filled with the filler material of the present invention should be understood as falling within the scope of the present invention.

Example 1: Preparation of Membrane

15

A batch of about 200 porcine peritoneal membranes, each measuring about 20 x 30 cm are obtained from a slaughterhouse and, if necessary, mechanically freed of fatty residues. These membranes, which weigh about 10
20 kg, are washed for about 4 hours with running tap water at about 45°C in a rotating drum and then washed three more times with 40 l. of room temperature tap water.

After the washing steps have been completed, the
25 membranes are soaked in 40 l. of a 0.5% (w/w) solution of sodium hydroxide (NaOH) in tap water for up to 13 days at room temperature until the amido nitrogen content is reduced by about one half to original value or to about 0.35 m mol/g. or less. During this period,
30 the NaOH solution may be refreshed several times. Thereafter, the membranes are again washed 3 times with 40 l. of room temperature tap water.

Next, the membranes are soaked for 4 hours in a room
35 temperature solution of hydrochloric acid (HCl). The HCL solution is prepared by mixing 4 l. of concentrated (37%) HCl with 36 l. of tap water.

- 11 -

After completion of the acid treatment, the membranes are washed with tap water until the pH of the wash water is between 2.5 and 3. The remaining acid is then neutralized by soaking the membranes overnight in 50 l. of tap water to which 350 g. sodium hydrogen carbonate (NaHCO_3) has been added.

There then follows another tap water wash to remove the salts formed during neutralization. Samples of the wash water are periodically mixed with a silver nitrate (AgNO_3) solution. When mixing with the AgNO_3 solution no longer produces precipitates, removal of salts is deemed complete.

Water is then removed from the membranes by means of acetone extractions. Finally, the acetone is removed by air drying while the membranes are kept in constant motion.

Example 2: Preparation of Filler Material

A 10 kg batch of bovine ligamentum nuchae which has been mechanically freed of fatty residues is soaked overnight in about 40 l. of tap water at room temperature. This initial soak removes adherent blood and other water soluble components and also assures a more or less natural degree of hydration which is believed to facilitate the subsequent chemical treatments.

The ligaments are then washed twice for about 10 minutes each with 50 l. of tap water, before being placed in 50 l. of a 4% (w/w) solution of sodium hydroxide (NaOH) in tap water. They are permitted to remain in this strongly alkaline soak for 48 hrs. at room temperature.

- 12 -

The alkaline soak is followed by three 10 minute washes in 50 l. of tap water. The ligaments are then subjected to a second alkaline soak, this one in 50 l. of a 2% (w/w) solution of NaOH in tap water at room temperature for 72 hrs. After removal from the second alkaline soak they are washed three more times for 10 minutes in 30 l. of tap water to remove the solubilized components.

Next, the ligaments are placed in a solution of hydrochloric acid (HCl) for about 4 hr. The HCl solution for this soak is prepared by mixing 4 l. concentrated (37%) HCl with 36 l. of tap water. The acid soaked ligaments are then washed in tap water until the pH of the wash water is between about 2.5 and 3.

The ligaments are then placed in an NaHCO₃ soak to neutralize the remaining acid. The NaHCO₃ soak is prepared by adding 350 gm. of NaHCO₃ to 50 l. of tap water. The ligaments are left in this neutralizing bath overnight and then they are again washed in tap water to remove the resulting salts. Washing continues until mixing with a silver nitrate (AgNO₃) solution produces no precipitates.

A kolloid mill is then used to separate the natural elastin fibers. Fiber length may also be reduced in the kolloid mill. Acetone extractions are then used to remove the water and, finally, the fibers are air dried in an oven at about 75°C.

The filler material which emerges from this process is a fluffy mass of elastin and collagen fibers. They may be used in that state or they may be compressed and molded to any desired shape.

- 13 -

Example 3: Preparation of Envelope or Pouch

Two dried membranes, prepared in accordance with Example 1 above, are cut into circles of about 12 cm. in diameter. The edges are sewn together using prolene suture material to form an envelope or pouch. While non-adsorbable suture material like prolene is thought to be preferable, absorbable sutures like polylactide or polyglycolide may also be suitable.

When the membrane edges are sewn together, one section of the periphery is left unsewn and 30 gm. of filler material, prepared in accordance with Example 2 above, is inserted through the unsewn section. The unsewn section is then sewn shut.

In the examples above, both the membranes and the filler material are dried at the end of the cleaning processes. This facilitates handling during the sewing and filling of the pouch. A pouch made of dry materials is more easily sterilized than is one made of wet components. Also, pouches are more easily stored in the dry state and sterility is more easily maintained over extended periods of time when all the materials are dry. Nevertheless, although drying is preferred before preparation of the implant pouch, it is not absolutely necessary.

Finally, approximately 30 minutes before implant surgery, the sterile, dry pouch is hydrated, for example, in sterile water or phosphate buffered saline. The pouch is then implanted in the wet state.

With implants according to the present invention, even after implantation has been completed, the degree of augmentation can still be changed. For example, if the amount of augmentation is found to be insufficient,

- 14 -

additional filling material can be injected into the pouch through an hypodermic needle. For such purpose, the filling material would normally be suspended in a biocompatible carrier such as glycerine and water.

5 Because of the nature of the pouch membrane, the hole made by the needle is self sealing and hence seepage of filling material into the surrounding tissue would be minimal to non-existent. Moreover, since the filling material is non-cytotoxic, whatever seepage that might
10 occur would be of no concern.

Similarly, if the degree of augmentation is too great, an hypodermic needle could be used to extract some of the filling material. Were this to be done, however,
15 it would have to be done before there has been significant ingrowth.

While it is believed that breast augmentation and breast reconstruction are the fields in which the
20 present invention will likely find its most immediate utility, this invention is not limited to such uses. For example, implants in accordance with the present invention could be used to build up portions of a person's face, arms, thighs or buttocks. In fact, an
25 envelope made in accordance with this invention could be implanted into any soft tissue in the body.

It will readily be apparent to those skilled in the art that numerous modifications, alterations and changes
30 can be made without departing from the inventive concept described herein. Accordingly, all such variants should be viewed as being within the scope of the invention as set forth in the claims below.

- 15 -

WHAT IS CLAIMED IS:

1. A soft tissue implant comprising
an outer membrane formed into a closed pouch and
filling material in said pouch,
said filling material having collagen as a component
thereof and wherein said collagen is not cross-linked.
2. A tissue implant in accordance with claim 1
wherein said filling material is comprised of elastin
and collagen.
3. A tissue implant in accordance with claim 2
wherein there is more elastin than collagen in said
filling material.
4. A tissue implant in accordance with claim 1
wherein the membrane of said pouch is comprised of a
natural collagen/elastin matrix which has been cleaned
of non-collagenous proteins.
5. A tissue implant in accordance with claim 1
wherein the membrane of said pouch is comprised of
silicone.
6. A soft tissue implant comprising
an outer membrane formed into a closed pouch and
filling material in said pouch,
said outer membrane having been derived from natural
animal membrane from which non-collagenous and non-
elastinuous components have been removed and said
filling material having non-cross-linked collagen as a
component.
7. A tissue implant in accordance with claim 6
wherein said filling material is derived from animal

- 16 -

tissue selected from the group comprising ligaments, membranes and tendons.

8. A tissue implant in accordance with claim 7 wherein said animal ligaments, membranes or tendons have been treated to remove non-elastinuous and non-collagenous proteins.

9. A tissue implant in accordance with claim 8 wherein said filling material is derived from bovine ligamentum nuchae.

10. A soft tissue implant comprised of a pouch and filling material, said pouch being formed of natural animal membrane which has been treated to remove non-elastinuous and non-collagenous proteins without destroying the natural collagen-elastin matrix, said filling material including collagen.

11. A tissue implant in accordance with claim 10 herein said animal membrane is selected from the group comprising the peritoneum, omentum, amnion, chorion, pleura, pericardium, facia lata, dura mater, intestine and dermis.

12. A tissue implant in accordance with claim 10 herein said treated animal membrane has a loose connective tissue side and a mesothelial side and wherein said pouch is made with said loose connective tissue side out.

13. A tissue implant in accordance with claim 10 herein said filling material has as its major components elastin and collagen.

14. A tissue implant according to claim 13 wherein said elastin and said collagen of said filling material

- 17 -

have been treated to remove non-elastinous and non-collagenous proteins.

15. A tissue implant according to claim 14 wherein said collagen and said elastin of said filling material are in the form of fibers and wherein the collagen has not been cross-linked.

16. A tissue implant in accordance with claim 10 wherein said implant is a breast prosthesis.

17. A soft tissue implant comprising
an outer membrane formed into a closed pouch and
filling material in said pouch,
said filling material having collagen as a component
thereof and wherein said collagen has been cross-linked
with a compound selected from the group consisting of
hexamethylene diisocyanate, polyepoxide and water
soluble carbodiimides.

18. A soft tissue implant comprising
an outer membrane formed into a closed pouch and
filling material in said pouch,
said outer membrane having collagen as a component
thereof and wherein said collagen has been cross-linked
with a compound selected from the group consisting of
hexamethylene diisocyanate, polyepoxide and water
soluble carbodiimides.

19. A composition for use as a filler material in a
soft tissue implant comprising elastin and collagen.

20. A composition according to claim 19 wherein said
elastin is at least 10% by weight of the combined dry
weight of elastin plus collagen.

- 18 -

21. A composition according to claim 19 wherein said elastin content is at least 50% of said combined dry weight.

22. A composition according to claim 19 wherein said elastin content is at least 70% of said combined weight.

23. A composition according to claim 19 wherein said elastin and said collagen are derived, at least in part, from different tissue sources.

24. A composition according to claim 19 wherein said elastin and collagen have been treated to remove non-collagenous and non-elastinuous proteins.

25. A composition according to claim 19 wherein said collagen has not been cross-linked.

26. A composition according to claim 19 wherein said collagen has been cross-linked with a compound selected from the group comprising hexamethylene diisocyanate, a polyepoxy and a water soluble carbodiimide.

27. A composition according to claim 19 wherein said elastin and said collagen have been derived from the ligamentum nuchae.

28. A method of breast augmentation comprising implanting into the breast a soft tissue implant in accordance with claim 1.

29. The method of claim 28 further comprising the step of changing the size of said implant after implantation thereof by injecting or removing said filling material into said pouch through an hypodermic needle.

- 19 -

30. A method of making a soft tissue implant pouch containing filling material wherein said pouch is made of a membrane derived from natural animal membrane selected from the group comprising the peritoneum, omentum, amnion, chorion, pleura, pericardium, fascia lata, dura mater, intestine and dermis and wherein said filling material is derived from a starting material selected from the group comprising animal ligaments, membranes and tendons, said method comprising treating said natural animal membrane, treating said filling material before, after or simultaneously with treating said natural animal membrane, forming said treated animal membrane into a partially closed pouch, placing said treated filling material into said partially closed pouch and then closing the rest of the pouch.

31. The method of claim 30 wherein said natural animal membrane is treated using a process comprising the steps of

- washing said membrane in water,
- treating the washed membrane with a strong alkali,
- treating said membrane with an acid, and
- treating said membrane with a base to neutralize the acid.

32. The method of claim 31 further comprising the step of drying said membrane after said neutralizing step.

33. The method of claim 30 wherein said filling starting material is treated using a process comprising the steps of

- treating said starting material with a strong alkali solution,
- treating the starting material with an acid,
- treating the starting material with a base to neutralize the acid, and

- 20 -

- mechanically working the starting material to separate the elastin fibers.

34. The method of claim 33 further comprising the step of drying said filling material after said neutralizing step.

35. The method of claim 33 wherein said starting material is bovine ligamentum nuchae.


36. The method of claim 30 wherein said pouch membrane is prepared by a process according to claim 31 and said filling material is prepared by a process according to claim 33.

37. The method of claim 30 wherein said pouch is made by sewing together two pieces of treated natural animal membrane around the periphery of said pouch.

38. The method of claim 30 wherein said pouch is made of a single piece of treated natural animal membrane which has been folded and sewn around the periphery of said pouch.

1/1

FIG. 1



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/10222

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61B 19/00; A61F 2/12

US CL :128/898; 623/008

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : DIG. 8; 128/898; 424/484; 514/21; 623/007, 008, 011

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

Search Terms: collagen, elastin, implant, ligamentum nuchae, crosslink?, polyepoxy, carbodiimide,

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,597,762, (WALTER ET AL.), 01 June 1986. See column 3, lines 43-48.	1-11, 13-18, 20-22, 24-38
X	US, A, 4,291,013, (WAHLIG ET AL.), 22 September 1981. See entire document.	19, 23
Y	US, A, 5,206,028, (LI), 27 April 1993. See entire document.	17, 18, 26
Y	US, A, 4,474,763, (LUBOWE), 02 October 1984. See entire document.	9, 22, 27
Y	US, A, 4,801,299, (BRENDEN et al.), 31 January 1989. See entire document.	1-11, 13-22, 24-38
Y	US, A, 5,219,360, (GEORGIADIS), 15 June 1993. See entire document.	5



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 OCTOBER 1994

Date of mailing of the international search report

DEC 28 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT CLARKE

Telephone No. (703) 308-2908